Abstract:Background: COVID-19 is an ongoing global pandemic. Changes in haematological characteristics in patients with COVID-19 are emerging as important features of the disease. We aimed to explore the haematological characteristics and related risk factors in patients with COVID-19. Methods: This retrospective cohort study included patients with COVID-19 admitted to three designated sites of Wuhan Union Hospital (Wuhan, China). Demographic, clinical, laboratory, treatment, and outcome data were extracted from electronic medical records and compared between patients with moderate, severe, and critical disease (defined according to the diagnosis and treatment protocol for novel coronavirus pneumonia, trial version 7, published by the National Health Commission of China). We assessed the risk factors associated with critical illness and poor prognosis. Dynamic haematological and coagulation parameters were investigated with a linear mixed model, and coagulopathy screening with sepsis-induced coagulopathy and International Society of Thrombosis and Hemostasis overt disseminated intravascular coagulation scoring systems was applied. Findings: Of 466 patients admitted to hospital from Jan 23 to Feb 23, 2020, 380 patients with COVID-19 were included in our study. The incidence of thrombocytopenia (platelet count <100 x 109 cells per L) in patients with critical disease (42 [49%] of 86) was significantly higher than in those with severe (20 [14%] of 145) or moderate (nine [6%] of 149) disease (p<0.0001). The numbers of lymphocytes and eosinophils were significantly lower in patients with critical disease than those with severe or moderate disease (p<0.0001), and prothrombin time, D-dimer, and fibrin degradation products significantly increased with increasing disease severity (p<0.0001). In multivariate analyses, death was associated with increased neutrophil to lymphocyte ratio (>= 9.13; odds ratio [OR] 5.39 [95% CI 1.70-17.13], p=0.0042), thrombocytopenia (platelet count <100 x 109 per L; OR 8.33 [2.56-27.15], p=0.00045), prolonged prothrombin time (>16 s; OR 4.94 [1.50-16.25], p=0.0094), and increased D-dimer (>2 mg/L; OR 4.41 [1.06-18.30], p=0.041). Thrombotic and haemorrhagic events were common complications in patients who died (19 [35%] of 55). Sepsis-induced coagulopathy and International Society of Thrombosis and Hemostasis overt disseminated intravascular coagulation scores (assessed in 12 patients who survived and eight patients who died) increased over time in patients who died. The onset of sepsis-induced coagulopathy was typically before overt disseminated intravascular coagulation. Interpretation: Rapid blood tests, including platelet count, prothrombin time, D-dimer, and neutrophil to lymphocyte ratio can help clinicians to assess severity and prognosis of patients with COVID-19. The sepsis-induced coagulopathy scoring system can be used for early assessment and management of patients with critical disease. Copyright (C) 2020 Elsevier lid. All rights reserved.

Thrombocytopenia and its association with mortality in patients with COVID-19

SARS-CoV-2 Induced Thrombocytopenia As an Important Biomarker Significantly Correlated with Abnormal Coagulation Function, Increased Intravascular Blood Clot Risk and Mortality in COVID-19 Patients

Thrombocytopenia and increased risk of adverse outcome in COVID-19 patients

Association Between Platelet Parameters and Mortality in Coronavirus Disease 2019: Retrospective Cohort Study

Association Between Thrombocytopenia and 180-Day Prognosis of COVID-19 Patients in Intensive Care Units: A Two-Center Observational Study.

Thrombocytopenia is Associated with COVID-19 Severity and Outcome: an Updated Meta-Analysis of 5637 Patients with Multiple Outcomes

Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis

Hemorrhage and Venous Thromboembolism in Critically Ill Patients with COVID-19

Coagulation Dysfunction In Icu Patients With Coronavirus Disease 2019 In Wuhan, China: A Retrospective Observational Study Of 75 Fatal Cases

Haematological Characteristics and Risk Factors in the Classification and Prognosis Evaluation of COVID-19: a Retrospective Cohort Study.

COVID-19-associated coagulopathy: thromboembolism prophylaxis and poor prognosis in ICU

The decrease of CD4 T cell is associated with mortality in critical inpatients with COVID-19

Risk Factors for Systemic and Venous Thromboembolism, Mortality and Bleeding Risks in 1125 Patients with COVID-19: Relationship with Anticoagulation Status

Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment

Cumulative Evidence for the Association of Thrombosis and the Prognosis of COVID-19: Systematic Review and Meta-Analysis

Clinical characteristics and risk of death of 194 patients with severe covid-19

Meta-analysis of coagulation parameters associated with disease severity and poor prognosis of COVID-19

Mechanisms Involved in the Development of Thrombocytopenia in Patients with COVID-19

Severe Thrombocytopenia in a Patient with COVID-19

Abstract 11039: Platelets Contribute to Disease Severity in Covid-19

Association Between Risk of VTE and Mortality in Patients with COVID-19